Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Folliculin-interacting protein 2 (FNIP2) is a protein encoded by the FNIP2 gene, which acts as a binding partner for the tumor suppressor folliculin (FLCN) and AMP-activated protein kinase (AMPK). FNIP2 is a component of signaling pathways regulating cellular metabolism, nutrient sensing, and mTORC1 activity, particularly under conditions of varying amino acid availability. It helps promote FLCN recruitment to lysosomes and regulates the MiT/TFE family of transcription factors by modulating the mTORC1 pathway. FNIP2, together with FLCN, regulates autophagy and is involved in apoptosis in response to DNA damage by O6-methylguanine. FNIP2 also acts as a co-chaperone for Hsp90, modulating its ATPase activity and facilitating the chaperoning and stabilization of client proteins. Genetic studies link FNIP2 to obesity and leanness phenotypes, where certain variants in its 3’UTR affect mRNA stability and human body composition. FNIP2 plays a critical role in kidney tumor suppression in cooperation with FLCN and FNIP1, and disruption of its function is implicated in kidney cancer and Birt-Hogg-Dubé syndrome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Folliculin-interacting protein 2 (FNIP2).